BridgeBio Pharma (BBIO) Stock: Buy, Sell, or Hold?
BBIO - BridgeBio Pharma, Inc. Common Stock
$68.56
0.44 (0.65%)
▲
5d:
+3.27%
30d:
+3.44%
90d:
-18.5%
HOLD
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 04, 2026
11d
Get Alerted When BBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BBIO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: BBIO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: BBIO is currently trading at $68.56, which is considered extended relative to its 30-day fair value range of $65.27 to $68.48. From a valuation perspective, the stock is trading at a discount (Forward PE: -305.2) compared to its historical average (207.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BBIO is in a strong uptrend. The price is approaching resistance at $69.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 46/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $107.82 (+57.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BBIO is in a strong uptrend. The price is approaching resistance at $69.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 46/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $107.82 (+57.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$65.27 -
$68.48
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.7%
Protect Your Profits
Holding BBIO? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (46/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 57.3% below Wall St target ($107.82)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- NEUTRAL: Bottoming setup forming (46/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$65.27 -
$68.48
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$62.86
Resistance Level
$69.32
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-305.25
Wall Street Target
$107.82
(+57.3%)
Revenue Growth (YoY)
120.4%
Profit Margin
-97.0%
PE vs Historical
-305.3 vs 207.4
CHEAP
Share & Embed Analysis
Last updated: October 23, 2026 6:45 PM ET
Data refreshes hourly during market hours. Next update: 7:45 PM
Data refreshes hourly during market hours. Next update: 7:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
16 analysts |
$106 | 50 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
|
TSHA
Taysha Gene Therapies Inc |
STRONG BUY
13 analysts |
$13 | 58 HOLD |
Advanced BBIO Option Strategies
Professional options setups generated by AI based on today's BBIO price and gamma walls.
